Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Dermatologic Therapy

Volumn 21, Issue 3, 2008, Pages 167-179

  Popovich, Kyle J ^a,b   Hota, Bala ^b  

^a Stroger Cook County Hospital ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Community acquired infection; Staphylococcus aureus; Staphylococcus aureus skin infection

Indexed keywords

CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MINOCYCLINE; TIGECYCLINE; VANCOMYCIN;

BACTERIAL COLONIZATION; EPIDEMIC; HUMAN; HYGIENE; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; SKIN INCISION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; WOUND DRAINAGE;

ANTI-BACTERIAL AGENTS; CARRIER STATE; COMMUNITY-ACQUIRED INFECTIONS; DRAINAGE; DRUG ADMINISTRATION ROUTES; HUMANS; HYGIENE; METHICILLIN RESISTANCE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 45349089885     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00188.x     Document Type: Review

References (114)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998 : 339 : 520 532.
2. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006 : 44 : 108 118.
3. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005 : 352 : 1436 1444.
4. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005 : 352 : 1445 1453.
5. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005 : 40 : 100 107.
6. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated bloodstream infections. Clin Infect Dis 2006 : 42 : 647 656.
7. Popovich K, Hota B, Rice T, Aroutcheva A, Weinstein RA. A Phenotypic prediction rule for community-associated methicillin-Resistant Staphylococcus aureus. J Clin Microbiol 2007.
8. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003 : 41 : 5113 5120.
9. Berglund C, Molling P, Sjoberg L, Soderquist B. Predominance of staphylococcal cassette chromosome mec (SCCmec) type IV among methicillin-resistant Staphylococcus aureus (MRSA) in a Swedish county and presence of unknown SCCmec types with Panton-Valentine leukocidin genes. Clin Microbiol Infect 2005 : 11 : 447 456.
10. Robinson DA, Enright MC. Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2004 : 10 : 92 97.
11. Koreen L, Ramaswamy SV, Graviss EA, Naidich S, Musser JM, Kreiswirth BN. Spa typing method for discriminating among Staphylococcus aureus isolates. Implications for use of a single marker to detect genetic micro- and macrovariation. J Clin Microbiol 2004 : 42 : 792 799.
12. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006 : 355 : 666 674.
13. Popovich KJ Rice T, Aroutcheva A, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains replacing traditional nosocomial MRSA? (Oral Presentation). In: Abstracts, 17th Society for Healthcare Epidemiology of America Meeting; 2007 April 14-17; Baltimore USA; Society for Healthcare Epidemiology of America, pg 107.
14. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998 : 279 : 593 598.
15. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993 : 25 : 97 108.
16. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001 : 286 : 1201 1205.
17. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol 2004 : 42 : 4050 4053.
18. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-03. MMWR Morb Mortal Wkly Rep 2003 : 52 : 992 996.
19. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-03. MMWR Morb Mortal Wkly Rep 2003 : 52 : 88.
20. Methicillin-resistant staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-03. MMWR Morb Mortal Wkly Rep 2003 : 52 : 793 795.
21. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007 : 44 : 471 482.
22. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997 : 10 : 505 520.
23. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med 2001 : 344 : 11 16.
24. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005 : 45 : 311 320.
25. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006 : 193 : 172 179.
26. Creech CB 2nd, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005 : 24 : 617 621.
27. Nakamura MM, Rohling KL, Shashaty M, Lu H, Tang YW, Edwards KM. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J 2002 : 21 : 917 922.
28. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004 : 39 : 971 979.
29. Hota B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW, Weinstein RA. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital. Do public housing and incarceration amplify transmission? Arch Intern Med 2007 : 167 : 1026 1033.
30. Shahin R, Johnson IL, Jamieson F, McGeer A, Tolkin J, Ford-Jones EL. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 1999 : 153 : 864 868.
31. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999 : 43 : 1412 1416.
32. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000 : 31 : 1380 1385.
33. Gorwitz RJ, JD, Powers JH, Jernigan JA Participants in the CDC-Convened Experts' Meeting on the Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. [Online] http://www.cdcgov/ncidod/dhqp/ar_mrsa_cahtml 2006.
34. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J 2004 : 23 : 123 127.
35. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. Impact of antimicrobial therapy on outcome. Clin Infect Dis 2007 : 44 : 777 784.
36. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 : 41 : 1373 1406.
37. Barnes EV 2nd, Dooley DP, Hepburn MJ, Baum SE. Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med 2006 : 171 : 504 507.
38. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007 : 51 : 423 428.
39. Kaka AS, Rueda AM, Shelburne SA 3rd, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006 : 58 : 680 683.
40. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007 : 51 : 2628 2630.
41. Martinez-Aguilar G, Hammerman WA, Mason EO Jr., Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003 : 22 : 593 598.
42. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005 : 128 : 2732 2738.
43. Tamayo J, Perez-Trallero E, Gomez-Garces JL, Alos JI. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother 2005 : 56 : 780 782.
44. Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005 : 41 : 599 608.
45. Patel M, Waites KB, Moser SA, Cloud GA, Hoesley CJ. Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J Clin Microbiol 2006 : 44 : 2481 2484.
46. Huang H, Flynn NM, King JH, Monchaud C, Morita M, Cohen SH. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol 2006 : 44 : 2423 2427.
47. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005 : 40 : 1429 1434.
48. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007 : 51 : 3298 3303.
49. Weese JS, Archambault M, Willey BM, et al. Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002. Emerg Infect Dis 2005 : 11 : 430 435.
50. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 in a Boston ambulatory health center. J Clin Microbiol 2007 : 45 : 1350 1352.
51. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay Area of northern California. J Clin Microbiol 1999 : 37 : 1727 1731.
52. Nielsen HU, Hammerum AM, Ekelund K, Bang D, Pallesen LV, Frimodt-Moller N. Tetracycline and macrolide co-resistance in Streptococcus pyogenes: co-selection as a reason for increase in macrolide-resistant S. pyogenes? Microb Drug Resist 2004 : 10 : 231 238.
53. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and - resistant Staphylococcus aureus. J Infect Dis 1991 : 163 : 1279 1285.
54. Strausbaugh LJ, Jacobson C, Sewell DL, Potter S, Ward TT. Antimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affairs nursing home care unit. Infect Control Hosp Epidemiol 1992 : 13 : 151 159.
55. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004 : 50 : 854 858.
56. Ellis MW, Lewis JS 2nd. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005 : 18 : 496 501.
57. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000 : 46 : 775 784.
58. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990 : 34 : 1227 1231.
59. Chang FY, Peacock JE Jr., Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003 : 82 : 333 339.
60. Fowler VG Jr., Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999 : 179 : 1157 1161.
61. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991 : 115 : 674 680.
62. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006 : 42 (Suppl. 1 S51 S57.
63. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004 : 42 : 2398 2402.
64. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007 : 44 : 1208 1215.
65. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 : 171 : 388 416.
66. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007 : 13 : 491 493.
67. Kleinschmidt SL, Munckhof WJ, Nimmo GR. In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur? Int J Antimicrob Agents 2006 : 27 : 168 170.
68. Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006 : 42 : 729 730.
69. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003 : 124 : 1789 1797.
70. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004 : 39 : 1010 1015.
71. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006 : 355 : 653 665.
72. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006 : 44 : 655 656.
73. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006 : 50 : 1079 1082.
74. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr., Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006 : 50 : 1581 1585.
75. Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006 : 42 : e108 110.
76. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004 : 26 : 704 714.
77. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004 : 48 : 137 143.
78. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005 : 40 : 1601 1607.
79. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003 : 26 : 511 532.
80. Appelbaum PC. MRSA - the tip of the iceberg. Clin Microbiol Infect 2006 : 12 (Suppl. 2 3 10.
81. Weston VC, Boswell TC, Finch RG, Perkins W. Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use. Bmj 2002 : 324 : 1394.
82. Gosbell IB. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004 : 5 : 239 259.
83. Halcon L, Milkus K. Staphylococcus aureus and wounds: a review of tea tree oil as a promising antimicrobial. Am J Infect Control 2004 : 32 : 402 408.
84. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004 : 56 : 283 286.
85. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007 : 356 : 479 485.
86. McMahon MA, Blair IS, Moore JE, McDowell DA. Habituation to sub-lethal concentrations of tea tree oil (Melaleuca alternifolia) is associated with reduced susceptibility to antibiotics in human pathogens J Antimicrob Chemother 2007 : 59 : 125 127.
87. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006 : 50 : 3882 3885.
88. Eveillard M, de Lassence A, Lancien E, Barnaud G, Ricard JD, Joly-Guillou ML. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006 : 27 : 181 184.
89. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000 : 21 : 459 464.
90. Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, Wenzel RP. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994 : 154 : 1505 1508.
91. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002 : 346 : 1871 1877.
92. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996 : 156 : 1109 1112.
93. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin- resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007 : 51 : 3591 3598.
94. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006 : 367 : 731 739.
95. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother 2007 : 51 : 2048 2052.
96. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de Mol BA. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 2006 : 296 : 2460 2466.
97. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006 : 63 (Suppl. 1 S1 S44.
98. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit. Role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006 : 27 : 185 187.
99. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007 : 44 : 178 185.
100. Dellit T, DJ, Hofmann J, Olson EG. Interim guidelines for evaluation and management of community-associated methicillin-resistant staphylococcus aureus skin and soft tissue infections in outpatient settings. http://www.dohwagov/ Topics/Antibiotics/MRSAInterimhtm September2, 2004.
101. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986 : 315 : 91 96.
102. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988 : 260 : 2682 2685.
103. Martin MA. Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Curr Clin Top Infect Dis 1994 : 14 : 170 191.
104. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002 : 346 : 491 496.
105. Hota B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 2004 : 39 : 1182 1189.
106. Rihn JA, Posfay-Barbe K, Harner CD, et al. Community-acquired methicillin-resistant Staphylococcus aureus outbreak in a local high school football team unsuccessful interventions. Pediatr Infect Dis J 2005 : 24 : 841 843.
107. Wootton SH, Arnold K, Hill HA, et al. Intervention to reduce the incidence of methicillin-resistant Staphylococcus aureus skin infections in a correctional facility in Georgia. Infect Control Hosp Epidemiol 2004 : 25 : 402 407.
108. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007 : 44 : e88 95.
109. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003 : 24 : 362 386.
110. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996 : 17 : 53 80.
111. Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002 : 51 (RR-16 1 45, quiz CE1 4.
112. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007 : 298 : 1763 1771.
113. Huijsdens XW, van Santen-Verheuvel MG, Spalburg E, et al. Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2006 : 44 : 2994 2996.
114. Saiman L, O'Keefe M, Graham PL 3rd, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003 : 37 : 1313 1319.